2025 SENATE HUMAN SERVICES
SB 2196

2025 SENATE STANDING COMMITTEE MINUTES

Human Services Committee

Fort Lincoln Room, State Capitol

SB 2196 1/21/2025

Relating to student self-administration of asthma or anaphylaxis medication.

9:31 a.m. Chairman Lee opened the hearing.

Members Present: Chairman Lee, Vice-Chairman Weston, Senator Van Oosting, Senator Clemens, Senator Hogan, Senator Roers.

Discussion Topics:

- Technical correction
- Weight recommendation
- School Nurses
- 9:31 a.m. Senator Kristen Roers testified in favor.
- 9:33 a.m. Heather Kapella, Program Administrator for Special Health Services Unit, testified in favor and submitted testimony #30302.
- 9:38 a.m. Senator Roers moved a Do Pass.
- 9:38 a.m. Senator Weston seconded the motion.

Senators	Vote
Senator Judy Lee	Υ
Senator Kent Weston	Υ
Senator David A. Clemens	Υ
Senator Kathy Hogan	Υ
Senator Kristin Roers	Υ
Senator Desiree Van Oosting	Υ

- 9:38 a.m. Motion passed 6-0-0.
- 9:39 a.m. Senator Van Oosting will carry the bill.
- 9:39 a.m. Chairman Lee closed the hearing.

Andrew Ficek, Committee Clerk

REPORT OF STANDING COMMITTEE SB 2196 (25.0778.01000)

Module ID: s_stcomrep_09_001

Carrier: Van Oosting

Human Services Committee (Sen. Lee, Chairman) recommends **DO PASS** (6 YEAS, 0 NAYS, 0 ABSENT AND NOT VOTING). SB 2196 was placed on the Eleventh order on the calendar. This bill does not affect workforce development.



Testimony Senate Bill No. 2196 Senate Human Services Committee Senator Judy Lee, Chair

January 21, 2025

Chair Lee, and members of the Senate Human Services Committee, I am Heather Kapella, I am a Program Administrator for the Special Health Services Unit. I also serve in the role of State School Nurse Consultant with the Department of Health and Human Services (Department). I appear before you in support of Senate Bill No. 2196, relating to student self-administration of asthma or anaphylaxis medication.

North Dakota Century Code 15.1-19-16 defines "emergency medication" as including a prescription drug that is delivered through inhalation to relieve asthmatic symptoms, as well as an epinephrine autoinjectable pen.

In August 2024, the Food and Drug Administration (FDA) announced the approval of Neffy, an epinephrine nasal spray, for the emergency treatment of allergic reactions, including life-threatening conditions like anaphylaxis, in adults and children weighing at least 66 pounds.

Epinephrine is the only life-saving treatment for anaphylaxis and was previously available only as an injection. The introduction of the epinephrine nasal spray may help eliminate barriers to quick treatment for anaphylaxis. This condition can be life-threatening, and some individuals, especially children, may hesitate or avoid treatment due to a fear of injections. Therefore, Neffy offers an important option for students to self-administer medication for anaphylaxis.

The proposed new language in Senate Bill No. 2196, which specifies that a device contains a premeasured dose of epinephrine, aligns with current FDA recommendations. This change supports the use of this new nasal spray treatment option while still permitting the use of an autoinjectable pen.

This concludes my testimony. I would be happy to try to answer any questions the committee may have. Thank you.

2025 HOUSE HUMAN SERVICES

SB 2196

2025 HOUSE STANDING COMMITTEE MINUTES

Human Services Committee

Pioneer Room, State Capitol

SB 2196 3/17/2025

Relating to student self-administration of asthma or anaphylaxis medication.

3:13 p.m. Chairman M. Ruby opened the hearing.

Members Present: Chairman M. Ruby, Representatives Beltz, Bolinske, Fegley, Hendrix,

Holle, Kiefert, Rios, Rohr

Members Absent: Vice-Chairman Frelich, Representatives K. Anderson, Davis, Dobervich

Discussion Topics:

Updates to the terms of emergency medications

3:13 p.m. Senator Roers, District 27, introduced the bill.

3:18 p.m. Heather Kapella, Special Health Services program administrator/state school nurse consultant of North Dakota Health Human Services, testified in favor and submitted testimony, #41713.

3:21 p.m. Chairman M. Ruby closed the hearing.

Jackson Toman, Committee Clerk



Testimony Senate Bill No.2196 House Human Services Committee Representative Matthew Ruby, Chairman March 17, 2025

Chairman Ruby, and members of the House Human Services Committee, I am Heather Kapella, a Program Administrator for the Special Health Services Unit. I also serve in the role of State School Nurse Consultant with the Department of Health and Human Services (Department). I appear before you in support of Senate Bill No. 2196, relating to student self-administration of asthma or anaphylaxis medication.

North Dakota Century Code 15.1-19-16 defines "emergency medication" as including a prescription drug that is delivered through inhalation to relieve asthmatic symptoms, as well as an epinephrine autoinjectable pen.

In August 2024, the Food and Drug Administration (FDA) announced the approval of Neffy, an epinephrine nasal spray, for the emergency treatment of allergic reactions, including life-threatening conditions like anaphylaxis, in adults and children weighing at least 66 pounds.

Epinephrine is the only life-saving treatment for anaphylaxis and was previously available only as an injection. The introduction of the epinephrine nasal spray may help eliminate barriers to quick treatment for anaphylaxis. This condition can be life-threatening, and some individuals, especially children, may hesitate or avoid treatment due to a fear of injections. Therefore, Neffy offers an important option for students to self-administer medication for anaphylaxis.



The proposed new language in SB 2196, which specifies that a device contains a premeasured dose of epinephrine, aligns with current FDA recommendations. This change supports the use of this new nasal spray treatment option while still permitting the use of an autoinjectable pen.

This concludes my testimony. I would be happy to try to answer any questions the committee may have. Thank you.

2025 HOUSE STANDING COMMITTEE MINUTES

Human Services Committee

Pioneer Room, State Capitol

SB 2196 3/19/2025

Relating to student self-administration of asthma or anaphylaxis medication.

9:38 a.m. Chairman M. Ruby opened the meeting.

Members Present: Chairman M. Ruby, Vice-Chairman Frelich, Representatives K. Anderson,

Beltz, Bolinske, Dobervich, Fegley, Holle, Kiefert, Rohr Members Absent: Representatives Davis, Hendrix, Rios

Discussion Topics:

Committee action

9:38 a.m. Representative Beltz moved a Do Pass.

9:39 a.m. Representative Rohr seconded the motion.

Representatives	Vote
Representative Matthew Ruby	Υ
Representative Kathy Frelich	Υ
Representative Karen Anderson	Υ
Representative Mike Beltz	Υ
Representative Macy Bolinske	Υ
Representative Jayme Davis	AB
Representative Gretchen Dobervich	Υ
Representative Cleyton Fegley	Υ
Representative Jared Hendrix	AB
Representative Dawson Holle	Υ
Representative Dwight Kiefert	Υ
Representative Nico Rios	AB
Representative Karen Rohr	Υ

9:41 a.m. Motion passed 10-0-3.

Representative Fegley will carry the bill.

9:41 a.m. Chairman M. Ruby closed the meeting.

Jackson Toman, Committee Clerk

REPORT OF STANDING COMMITTEE SB 2196 (25.0778.01000)

Module ID: h_stcomrep_43_016

Carrier: Fegley

Human Services Committee (Rep. M. Ruby, Chairman) recommends **DO PASS** (10 YEAS, 0 NAYS, 3 ABSENT OR EXCUSED AND NOT VOTING). SB 2196 was placed on the Fourteenth order on the calendar.